HMGCL

Across TCGA pan-cancer cohorts, HMGCL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HMGCL data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HMGCL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HMGCL expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where HMGCL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.991	0.837	<.001	36	view →
PDAC	DFS	Median	III,IV	0.369	0.885	.002	12	view →
LUAD	DFS	Tertile	All	0.481	0.788	.018	10	view →
COAD	DFS	Median	III,IV	1.000	0.847	.047	6	view →
LSCC	DFS	Median	All	0.604	0.822	.004	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HMGCL–CCRCC (DFS)

Open the CCRCC breakdown →